StockNews.AI
SF
StockNews.AI
141 days

Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum

1. Remix Therapeutics develops novel RNA-modulating therapies for disease treatment. 2. CEO Peter Smith will present at Stifel 2025 Virtual Oncology Forum on April 8. 3. Remix's REMaster™ technology enhances gene expression modulation. 4. The company is focused on addressing disease drivers at their origin. 5. Investors can schedule one-on-one meetings with Remix management.

3m saved
Insight
Article

FAQ

Why Bullish?

Remix Therapeutics is on the cutting edge of RNA therapy, indicating potential growth. Similar biotech firms have surged post announcements or successful presentations.

How important is it?

The innovative nature of Remix's therapies and upcoming presentation could attract investment.

Why Short Term?

The upcoming presentation may lead to immediate investor interest and stock movement.

Related Companies

RNACRSPEDITNTLA
March 31, 2025 07:00 ET  | Source: Remix Therapeutics WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 1:00 p.m. ET. For investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Stifel representative. About Remix TherapeuticsRemix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster™ technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the potential to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com. Contacts: Media Contact:Lisa BuffingtonBuffington Commslbuffington@remixtx.com Investor Contact:Will O'Connor  Precision AQWill.OConnor@precisionaq.com

Related News